Effect of MRI-guided intensity-modulated radiotherapy with bone marrow protection on hematologic toxicity in patients with rectal cancer undergoing concurrent chemoradiotherapy
Objective To reduce the radiation dose to the hematopoietic bone marrow (hBM) and acute hematologic toxicity (HT) in patients with rectal cancer undergoing intensity-modulated radiotherapy (IMRT). Methods The previously untreated patients with rectal cancer were enrolled in a prospective study. Pelvic magnetic resonance imaging (MRI) was used to determine and delineate the distribution of hBM,and dose limitations were set (V5<95%,V10<90%,V20<80%,V30<65%).The neoadjuvant therapeutic regimen included concurrent IMRT (95% PTV 50 Gy/25 fractions,2 Gy/fractions),oxaliplatin 50 mg/m2,qw,and capecitabine 1650 mg/m2,1 fractions/d (twice a day during radiotherapy). Results A total of 35 patients were enrolled and completed the therapeutic regimen. The incidence of grade 2-4 HT was 31.4%;among these patients,9(26%) experienced leucopenia,6(17%) experienced neutropenia,1(3%) experienced erythropenia,and 1(3%) experienced thrombocytopenia. No patients experienced grade ≥3 anemia. The multivariate logistic linear regression analysis showed that hBM-V5 was significantly correlated with the lowest counts of leukocytes (P=0.005),neutrophils (P=0.002),and platelets (P=0.017). Conclusions The radiation dose to the hBM in the pelvis on MRI is significantly correlated with the incidence and severity of acute HT in patients with rectal cancer undergoing neoadjuvant concurrent chemoradiotherapy.Clinical Trial Registry ClinicalTrials.gov,registration number:NCT01863420.
Wang Jianyang,Tian Yuan,Tang Yuan et al. Effect of MRI-guided intensity-modulated radiotherapy with bone marrow protection on hematologic toxicity in patients with rectal cancer undergoing concurrent chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2016, 25(3): 244-248.
[1] Sauer R,Becker H,Hohenberger W,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J].N Engl J Med,2004,351(17):1731-1740.DOI:10.1056/NEJMoa040694. [2] 金晶,李晔雄,王维虎,等.Ⅱ和Ⅲ期直肠癌术后卡培他滨±奥沙利铂同期放化疗急性副反应比较[J].中华放射肿瘤学杂志,2009,18(3):200-204.DOI:10.3760/cma.j.issn.1004-4221.2009.03.200. Jin J,Li YX,Wang WH,et al. Comparison of acute toxicities between two postoperative concurrent chemoradiotherapy regimens of capecitabine with or without oxaliplatin in patients with stage Ⅱ and Ⅲ rectal cancer[J].Chin J Radiat Oncol,2009,18(3):200-204.DOI:10.3760/cma.j.issn.1004-4221.2009.03.200. [3] 肖琴,金晶,李晔雄,等.局部晚期中低位直肠癌奥沙利铂联合卡培他滨术前同期放化疗的疗效分析[J].中华放射肿瘤学杂志,2014,23(2):99-103.DOI:10.3760/cma.j.issn.1004-4221.2014.02.005. Xiao Q,Jin J,Li YX,et al. The effect of oxaliplatin plus capecitabine in combination with radiation for locally advanced lower or middle sited rectal carcinoma[J].Chin J Radiat Oncol,2014,23(2):99-103.DOI:10.3760/cma.j.issn.1004-4221.2014.02.005. [4] Gérard JP,Azria D,Gourgou-Bourgade S,et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer[J].J Clin Oncol,2012,30(36):4558-4565.DOI:10.1200/JCO.2012.42.8771. [5] Ellis RE.The distribution of active bone marrow in the adult[J].Phys Med Biol,1961,5(3):255-258.DOI:10.1088/0031-9155/5/3/302. [6] Mauch P,Constine L,Greenberger J,et al. Hematopoietic stem cell compartment:acute and late effects of radiation therapy and chemotherapy[J].Int J Radiat Oncol Biol Phys,1995,31(5):1319-1339.DOI:10.1016/0360-3016(94)00430-S. [7] Rose BS,Aydogan B,Liang Y,et al. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2011,79(3):800-807.DOI:10.1016/j.ijrobp.2009.11.010. [8] Albuquerque K,Giangreco D,Morrison C,et al. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT[J].Int J Radiat Oncol Biol Phys,2011,79(4):1043-1047.DOI:10.1016/j.ijrobp.2009.12.025. [9] Brixey CJ,Roeske JC,Lujan AE,et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies[J].Int J Radiat Oncol Biol Phys,2002,54(5):1388-1396.DOI:10.1016/S0360-3016(02)03801-4. [10] Rose BS,Liang Y,Lau SK,et al. Correlation between radiation dose to 18F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2012,83(4):1185-1191.DOI:10.1016/j.ijrobp.2011.09.048. [11] Mell LK,Kochanski JD,Roeske JC,et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy[J].Int J Radiat Oncol Biol Phys,2006,66(5):1356-1365.DOI:10.1016/j.ijrobp.2006.03.018. [12] Roeske JC,Lujan A,Rotmensch J,et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies[J].Int J Radiat Oncol Biol Phys,2000,48(5):1613-1621.DOI:10.1016/S0360-3016(00)00771-9. [13] Mundt AJ,Lujan AE,Rotmensch J,et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies[J].Int J Radiat Oncol Biol Phys,2002,52(5):1330-1337.DOI:10.1016/S0360-3016(01)02785-7. [14] Roeske JC,Mundt AJ.Incorporation of magnetic resonance imaging into intensity modulated whole-pelvic radiation therapy treatment planning to reduce the volume of pelvic bone marrow irradiated[J].Int Congr Ser,2004,1268:307-312.DOI:10.1016/j.ics.2004.03.313. [15] Rdel C,Liersch T,Hermann RM,et al. Multicenter phase Ⅱ trial of chemoradiation with oxaliplatin for rectal cancer[J].J Clin Oncol,2007,25(1):110-117.DOI:10.1200/JCO.2006.08.3675. [16] Simon R.Optimal two-stage designs for phase Ⅱ clinical trials[J].Control Clin Trials,1989,10(1):1-10.DOI:10.1016/0197-2456(89)90015-9. [17] Sacks EL,Goris ML,Glatstein E,et al. Bone marrow regeneration following large field radiation. Influence of volume,age,dose,and time[J].Cancer,1978,42(3):1057-1065.DOI:10.1002/1097-0142(197809)42:3<1057::AID-CNCR2820420304>3.0.CO;2-P. [18] Blomlie V,Rofstad EK,Skjnsberg A,et al. Female pelvic bone marrow:serial MR imaging before,during,and after radiation therapy[J].Radiology,1995,194(2):537-543.DOI:10.1148/radiology.194.2.7824737. [19] Mell LK,Schomas DA,Salama JK,et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy[J].Int J Radiat Oncol Biol Phys,2008,70(5):1431-1437.DOI:10.1016/j.ijrobp.2007.08.074. [20] van de Bunt L,van der Heide UA,Ketelaars M,et al. Conventional,conformal,and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer:The impact of tumor regression[J].Int J Radiat Oncol Biol Phys,2006,64(1):189-196.DOI:10.1016/j.ijrobp.2005.04.025. [21] Lujan AE,Mundt AJ,Yamada SD,et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy[J].Int J Radiat Oncol Biol Phys,2003,57(2):516-521.DOI:10.1016/S0360-3016(03)00521-2. [22] Zhang FL,Zheng MM,Gao JM,et al. Bone marrow-sparing intensity-modulated radiotherapy for postoperative treatment of cervical cancer[J].Chin-Germ J Clin Oncol,2011,10(6):349-353.DOI:10.1007/s10330-011-0795-6. [23] 毛睿,齐洪志,尚革,等.Ⅱ期和Ⅲ期直肠癌术后盆腔调强放疗两种计划比较研究[J].中华放射肿瘤学杂志,2011,20(5):411-413.DOI:10.3760/cma.j.issn.1004-4221.2011.05.014. Mao R,Qi HZ,Shang G,et al. Dosimetric comparison of postoperative intensity-modulated radiotherapy for stage Ⅱ-Ⅲ rectal cancer[J].Chin J Radiat Oncol,2011,20(5):411-413.DOI:10.3760/cma.j.issn.1004-4221.2011.05.014. [24] Hayman JA,Callahan JW,Herschtal A,et al. Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging[J].Int J Radiat Oncol Biol Phys,2011,79(3):847-852.DOI:10.1016/j.ijrobp.2009.11.040.
2016, Vol. 25 
